Is Castle Biosciences, Inc. (CSTL) a Buy, Sell, or Hold?
NASDAQ : CSTL
Castle Biosciences, Inc.
$30.33 USD
-$0.07 (-0.23%)
- Volume
- 15.21K
- Average Volume
- 397.11K
- Market Capitalization
- $926.57M
- P/E Ratio
- -45.99
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $44.28
- Year Low
- $17.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.04
Company Overview
NASDAQ
Derek J. Maetzold
Medical - Diagnostics & Research
Healthcare
CSTL
883
US
USD
Liquidity Metrics
0.08
6.04
5.85
1.10
0.00
Sales & Valuation
$344.23M
2.59
1.96
-1894.82
-0.02
Profitability
-$0.83
-$24.16M
-5.43%
-5.37%
-4.15%
-3.46%
P/E Metrics
-45.99
0.46
0.46
Analyst Price Target & Rating
$40.00
$44.00
$35.00
2/5
11 Analysts
-24.17%
Financial Health Scores
6.80
3/9
$284.59M
$561.18M
$91.15M
-$18.83M
Key Metrics (TTM)
$903.24M
2.53
-279.12
6.04
-4.15%
-6.31%
-2.10%
-0.05%
53 days
Company Executives
| Name | Title |
|---|---|
| Jay Braxton | Vice President of Marketing & Brand Manager of Uveal Melanoma (UM) |
| Derek J. Maetzold | Founder, Chief Executive Officer, President & Director |
| Frank Stokes | Chief Financial Officer & Treasurer |
| Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs |
| Keli Greenberg | Vice President of Human Resources |
| Kristen Oelschlager | Chief Operating Officer |
| Trisha Poteet | Senior VP of Clinical Services & Manufacturing Operations |
| Kevin Doman | Vice President of Sales |
| Matthew Goldberg | Senior Vice President of Medical |
| Tobin W. Juvenal | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Castle Biosciences, Inc. (NASDAQ:CSTL) Stock
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test ... that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)
2026-08-04 02:15:45
Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Castle Biosciences
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
2026-07-31 03:53:18
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
2026-07-30 19:00:38
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to earnings of $0.15 per share a year ago.
Castle Biosciences Q2 Earnings Call Highlights
2026-07-30 18:06:22
Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous range of $345 million to $355 million.
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-07-22 07:00:00
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
2026-07-14 16:30:00
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis FRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).
2026-07-09 07:00:00
FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026. Company management will host a webcast to discuss its financial results at 4:30 p.m.
2026-06-25 16:30:00
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram Patients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN) 5% threshold used to consider avoiding sentinel lymph node biopsy (SLNB), compared with a 5.8% observed positivity rate for the MIA nomogram FRIENDSWOOD, Texas, June 25, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter study in Dermatology and Therapy demonstrating that DecisionDx-Melanoma's integrated sentinel lymph node biopsy test result (i31-SLNB) outperforms the MIA nomogram in identifying patients at low and high risk of SLN positivity, supporting more informed SLNB decision-making for patients with cutaneous melanoma (CM).1 This is the second multicenter study showing that the i31-SLNB result outperforms the MIA nomogram in assessing SLN positivity risk.2 "Many clinicians are familiar with nomograms that estimate risk of sentinel lymph node positivity using clinicopathologic features alone, yet current guidelines acknowledge limitations in their performance at lower risk thresholds," said Rohit Sharma, M.D., FACS, lead author of the study and surgical oncologist at Marshfield Clinic Health System in Marshfield, Wisconsin.
Frequently Asked Questions
-
What is the current Castle Biosciences, Inc. (CSTL) stock price?
-
Castle Biosciences, Inc.(NASDAQ:CSTL) stock price is $30.33 in the last trading session. During the trading session, CSTL stock reached the peak price of $44.28 while $17.722 was the lowest point it dropped to. The percentage change in CSTL stock occurred in the recent session was --0.23% while the dollar amount for the price change in CSTL stock was -$0.07.
-
CSTL's industry and sector of operation?
-
The NASDAQ listed CSTL is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of CSTL?
-
Jay Braxton | Vice President of Marketing & Brand Manager of Uveal Melanoma (UM)
Derek J. Maetzold | Founder, Chief Executive Officer, President & Director
Frank Stokes | Chief Financial Officer & Treasurer
Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs
Keli Greenberg | Vice President of Human Resources -
How many employees does CSTL have?
-
Number of CSTL employees currently stands at 883. CSTL operates from 1500 W. Parkwood Ave, Friendswood, TX 77546, US.
-
Link for CSTL official website?
-
Official Website of CSTL is: https://castlebiosciences.com
-
How do I contact CSTL?
-
CSTL could be contacted at phone #866 788 9007 and can also be accessed through its website. CSTL operates from 1500 W. Parkwood Ave, Friendswood, TX 77546, US.
-
How many shares of CSTL are traded daily?
-
The average number of CSTL shares traded daily for last 3 months was 397.11K.
-
What is the market cap of CSTL currently?
-
The market value of CSTL currently stands at $926.57M with its latest stock price at $30.33